Cambridge Investment Research Advisors, Inc.
Position in CRBU — Caribou Biosciences, Inc.
CIK 1419186
FAIRFIELD, IA
Position in CRBU
as of Mar 31, 2026
· filed Apr 30, 2026
Position Value
$1,039,326
+$114,276 QoQ
Shares Held
547,014
-6.0% QoQ
Ownership
0.552%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#20
of 137 holders
Holding Since
Mar 2025
5 quarters on record
Common Shares in CRBU Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Cambridge Investment Research Advisors, Inc. holds $49,299,867 across 75 Biotechnology names. CRBU ranks #11 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
15,955 | $7,124,545 | |
| 2 | EXEL |
Exelixis, Inc.
|
159,749 | $6,851,634 | |
| 3 | NKTR |
Nektar Therapeutics
|
56,055 | $4,033,157 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
4,832 | $3,733,396 | |
| 5 | IBRX |
ImmunityBio, Inc.
|
284,704 | $2,183,679 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
29,059 | $2,157,921 | |
| 7 | CRSP |
CRISPR Therapeutics AG
|
37,992 | $1,807,279 | |
| 8 | CORT |
Corcept Therapeutics Inc
|
42,754 | $1,723,413 |
All Filings in CRBU
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,039,326 | 547,014 | Shares | Sole | 2026-04-30 | |
| 2025-12-31 | $925,050 | 581,793 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $1,356,961 | 582,387 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $736,401 | 584,446 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $559,132 | 612,412 | Shares | Sole | 2025-04-22 | |
| No filing history on record for this holder in this stock. | ||||||